Breakthrough in colorectal cancer as Regeneron Pharmaceuticals reveals promising results from immunotherapy trial
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced encouraging early outcomes from its Phase 1/2 clinical trial, which evaluates a new immunotherapy combination of REGN7075 and ... Read More
Merck, Inspirna join forces to develop first-in-class oral cancer inhibitor
Merck, a renowned science and technology company, has reached a significant milestone in its efforts to combat cancer. The company announced a strategic licensing agreement ... Read More
Exscientia begins enrollment for Phase 1/2 cancer trial of CDK7 inhibitor
AI-driven precision medicine company Exscientia has initiated enrollment for its Phase 1/2 "ELUCIDATE" study, marking the first trial of its precision-designed CDK7 inhibitor, GTAEXS617 ('617), ... Read More
Natco Pharma wins FDA approval for generic colorectal cancer drug
Indian pharmaceutical firm Natco Pharma has gained the US Food and Drug Administration (FDA)'s final approval for its abbreviated new drug application (ANDA) for Tipiracil ... Read More
Lupin, Enzene Biosciences to launch cancer drug Cetuximab biosimilar in India
Lupin, an Indian pharmaceutical company, has announced a strategic collaboration with Enzene Biosciences, a subsidiary of Alkem Laboratories, to introduce Cetuximab in India. Cetuximab is ... Read More
Takeda signs licensing deal for Hutchmed’s fruquintinib outside of China
Takeda Pharmaceutical will acquire an exclusive worldwide license, excluding China, of fruquintinib from Hutchmed (China) and its subsidiary Hutchmed to strengthen its oncology portfolio. Under ... Read More
Seagen gets FDA accelerated approval for tucatinib, trastuzumab combo for colorectal cancer
American biotechnology company Seagen (formerly Seattle Genetics) has received accelerated approval from the US Food and Drug Administration (FDA) for the company’s oral drug Tukysa ... Read More
Biomea Fusion to take BMF-219 into clinical trials for KRAS solid tumors
Biomea Fusion is all set to take BMF-219 into clinical trials in patients having unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC), colorectal ... Read More
Chinese pharma giants Innovent Biologics and Shenzhen Chipscreen Biosciences join forces for advanced colorectal cancer drug trial
Innovent Biologics and Shenzhen Chipscreen Biosciences have entered into a major collaboration to assess the potential of a combination therapy for advanced colorectal cancer. The ... Read More
MedGenome study suggests cancer vaccine approach for treating Lynch Syndrome
Indian genomics research and diagnostics startup MedGenome recently unveiled promising results from a study on Lynch Syndrome, suggesting a novel approach using cancer vaccines to ... Read More